StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) shareholders

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.23−0.25 (-3.86%)

Close on Nov 17, 2026Market cap $668.01MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
115M of 107M shares
Institutional holders
156
36 new, 26 sold out
Net institutional buying
19M
In Q2 2026
Insider trades, 12 months
0 buys · 28 sales
Net sold $2.68M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Joseph Edelman
Joint filing with Perceptive Advisors LLC (11.20%), Perceptive Life Sciences Master Fund, Ltd. (11.20%)
12,046,57911.20%13D (active) amendmentJun 30, 2026
Rajeev Shah
Joint filing with RA Capital Management, L.P. (10.80%), Peter Kolchinsky (10.80%) and 1 more
12,036,12610.80%13D (active) amendmentNov 4, 2026
Perceptive Advisors LLC
Joint filing with Joseph Edelman (12.90%), Perceptive Life Sciences Master Fund, Ltd. (12.80%)
11,969,07912.90%13D (active) amendmentMar 9, 2026
Raymond Debbane
Joint filing with Invus Public Equities, L.P. (8.70%), Invus Public Equities Advisors, LLC (8.70%) and 2 more
10,066,6829.99%13G (passive) amendmentMar 31, 2026
Peter Kolchinsky
Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more
9,313,7569.90%13D (active) amendmentMar 13, 2026
BCLS II Investco, LP
Joint filing with Bain Capital Life Sciences Opportunities IV, L.P. (5.40%)
8,604,8528.80%13D (active) amendmentMar 6, 2026
Abigail P. Johnson
Joint filing with FMR LLC (7.00%)
6,875,9577.00%13G (passive)Jun 30, 2026
Robert Atchinson
Joint filing with Adage Capital Management, L.P. (8.68%), Phillip Gross (8.68%)
6,729,4848.68%13G (passive)Mar 31, 2025
BlackRock, Inc.6,419,7306.50%13G (passive)Jun 30, 2026
Commodore Capital LP
Joint filing with Commodore Capital Master LP (7.60%)
5,825,0007.60%13G (passive)Feb 18, 2025
Phillip Gross
Joint filing with Adage Capital Management, L.P. (5.14%), Robert Atchinson (5.14%)
4,000,0005.14%13G (passive) amendmentSep 30, 2025
Stichting Administratiekantoor Westend
Joint filing with Invus Public Equities, L.P. (7.30%), Invus Public Equities Advisors, LLC (7.30%) and 5 more
2,717,5387.30%13G (passive)Jan 11, 2024
Adage Capital Partners GP, L.L.C.
Joint filing with Adage Capital Partners, L.P. (7.25%), Adage Capital Management, L.P. (7.25%) and 2 more
2,712,4787.25%13G (passive)Jan 8, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SLDBValueChange% of portfolio
Ra Capital Management, L.P.12,036,12611.23%$120.24M+2,696,1481.04%
Perceptive Advisors LLC11,906,64611.10%$118.95M–1.79%
Bain Capital Life Sciences Investors, LLC9,808,8199.15%$97.99M–5.83%
Siren, L.L.C.7,690,4057.17%$76.83M–1.55%
BlackRock, Inc.6,934,2486.47%$69.27M+1,975,8940.00%
FMR LLC6,875,9576.41%$68.69M+3,269,5530.00%
Armistice Capital, LLC4,278,0003.99%$42.74M+1,078,0000.52%
State Street Corp4,175,3653.89%$41.71M+3,049,8780.00%
Jupiter Topco LLC4,043,6053.77%$40.38MNew0.02%
Vanguard Capital Management LLC4,009,9223.74%$40.06M+1,335,2980.00%
Rtw Investments, LP3,892,9263.63%$38.89MNew0.33%
Deep Track Capital, LP3,565,0623.32%$35.61M–0.52%
Franklin Resources Inc3,440,7083.21%$34.37M+1,247,7710.01%
Citadel Advisors LLC2,815,1222.63%$28.12M+218,3220.00%
Alyeska Investment Group, L.P.2,280,4842.13%$22.78M+3590.06%
Ameriprise Financial Inc2,225,7832.08%$22.24M−213,0660.00%
Vestal Point Capital, LP2,160,0002.01%$21.58M−2,840,0000.50%
Redmile Group, LLC1,948,6951.82%$19.47M−63,2001.31%
Geode Capital Management, LLC1,940,8241.81%$19.39M+644,8400.00%
Goldman Sachs Group Inc1,602,9171.49%$16.01M+667,3820.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026156115M100.0%36 / 5940 / 2629M10M
Q1 2026150100M93.2%34 / 5441 / 1227M5M
Q4 202513081M75.9%14 / 3746 / 1110M10M
Q3 202512781M75.9%25 / 3836 / 127M8M
Q2 202511483M77.0%25 / 5414 / 3518M14M
Q1 202512479M73.5%50 / 4315 / 1546M3M
Q4 20249036M33.9%16 / 3520 / 184M3M
Q3 20249236M33.4%27 / 2821 / 137M7M
Q2 20248038M35.1%31 / 2317 / 68M5M
Q1 20245535M32.7%22 / 242 / 620M2M
Q4 20233917M15.5%8 / 145 / 51M1M
Q3 20233616M15.1%3 / 78 / 30M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

143 funds held SLDB in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SLDBValue% of fundAs of
Vanguard Total Stock Market Index Fund3,148,5762.94%$31.45M0.00%Jun 30, 2026
Select Biotechnology Portfolio2,606,7792.43%$19.13M0.36%May 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,582,2692.41%$25.80M0.24%Jun 30, 2026
iShares Russell 2000 ETF2,052,9841.91%$20.51M0.02%Jun 30, 2026
Columbia Small Cap Growth Fund1,476,0301.38%$10.83M0.30%May 31, 2026
Franklin Biotechnology Discovery Fund1,409,0931.31%$11.36M0.98%Jul 31, 2026
Fidelity Small Cap Index Fund862,7140.80%$6.95M0.02%Jul 31, 2026
Vanguard Extended Market Index Fund774,0060.72%$7.73M0.01%Jun 30, 2026
Fidelity Advisor Biotechnology Fund677,5650.63%$5.46M0.25%Jul 31, 2026
iShares Biotechnology ETF551,5910.51%$5.51M0.06%Jun 30, 2026
Fidelity Series Small Cap Core Fund500,0000.47%$4.03M0.26%Jul 31, 2026
Columbia Small Cap Value Discovery Fund449,5260.42%$3.62M0.15%Jul 31, 2026
Fidelity Enhanced Small Cap Core ETF427,8810.40%$4.27M0.07%Jun 30, 2026
iShares Russell 2000 Value ETF373,8280.35%$3.73M0.03%Jun 30, 2026
iShares Russell 2000 Growth ETF359,2570.34%$3.59M0.02%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Alexander CumboPresident and CEO, Director235,4050.22%Apr 21, 2026
Gabriel BrooksChief Medical Officer97,2410.09%Oct 20, 2026
Kevin TanCFO & Treasurer99,4220.09%Apr 21, 2026
Jessie HanrahanChief Regulatory Officer74,3180.07%Apr 21, 2026
Paul HerzichChief Technology Officer72,6380.07%Apr 21, 2026
David T. HowtonChief Operating Officer105,0770.10%Apr 21, 2026
Ilan GanotDirector146,1650.14%Oct 26, 2026
Ian F. SmithDirector141,5850.13%Oct 6, 2026
Clare KahnDirector2,9600.00%Jun 11, 2026
Advisors Llc PerceptiveDirector, 10% owner6,749,8036.29%Jun 11, 2026
Life Sciences Master Fund Ltd PerceptiveDirector, 10% owner––Jun 11, 2026
Joseph EdelmanDirector, 10% owner11,833,53911.04%Jun 11, 2026
Adam Leo StoneDirector0–Jun 11, 2026
Sukumar NagendranDirector34,2580.03%Jun 11, 2026
Lynne Marie SullivanDirector––Jun 11, 2026
Martin I. FreedDirector53,7630.05%Jun 11, 2026
Georgia KerestyDirector––Jun 11, 2026
Perceptive Xontogeny Venture Fund, LPDirector, 10% owner6,833,5396.37%Feb 21, 2025
Rajeev M. Shah10% owner8,709,8828.12%Jun 24, 2026
Peter Kolchinsky10% owner109,6610.10%Jun 24, 2026
Ra Capital Management, L.P.10% owner2,987,6442.79%Jun 24, 2026
Capital Healthcare Fund LP RA10% owner787,5860.73%Jun 24, 2026
BCLS II Equity Opportunities, LP10% owner––Feb 21, 2025
Bain Capital Life Sciences Investors, LLC10% owner––Feb 21, 2025
Bain Capital Life Sciences Partners, LP10% owner––Feb 21, 2025
BCIP Life Sciences Associates, LP10% owner––Feb 21, 2025
Bain Capital Life Sciences Investors II, LLC10% owner––Feb 21, 2025
BCLS II Investco, LP10% owner––Feb 21, 2025
BCLS II Investco (GP), LLC10% owner––Feb 21, 2025
Bain Capital Life Sciences Fund II, L.P.10% owner3,130,4232.92%Feb 21, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gabriel Brooks
Chief Medical Officer
Oct 19, 2026Sale(10b5-1 plan)−4,374$5.62$24.58K97,241
Gabriel Brooks
Chief Medical Officer
Oct 18, 2026Option exercise+9,750––101,615
Ian F. Smith
Director
Oct 2, 2026Option exercise+3,440––141,585
Ian F. Smith
Director
Jul 2, 2026Option exercise+3,440––138,145
Ian F. Smith
Director
Apr 2, 2026Option exercise+3,441––134,705
Alexander Cumbo
President and CEO, Director
Feb 18, 2026Sale(10b5-1 plan)−16,644$5.82$96.87K235,405
Ilan Ganot
Director
Feb 18, 2026Sale(10b5-1 plan)−2,658$5.82$15.47K27,474
Paul Herzich
Chief Technology Officer
Feb 18, 2026Sale(10b5-1 plan)−3,616$5.82$21.05K72,638
David T. Howton
Chief Operating Officer
Feb 18, 2026Sale(10b5-1 plan)−7,469$5.82$43.47K105,077
Jessie Hanrahan
Chief Regulatory Officer
Feb 18, 2026Sale(10b5-1 plan)−4,134$5.82$24.06K74,318
Gabriel Brooks
Chief Medical Officer
Feb 18, 2026Sale(10b5-1 plan)−0$5.82$089,466
Kevin Tan
CFO & Treasurer
Feb 18, 2026Sale(10b5-1 plan)−5,404$5.82$31.45K99,422
Alexander Cumbo
President and CEO, Director
Feb 13, 2026Option exercise+30,031––252,049
Ilan Ganot
Director
Feb 13, 2026Option exercise+4,861––30,132
Paul Herzich
Chief Technology Officer
Feb 13, 2026Option exercise+7,187––76,254
David T. Howton
Chief Operating Officer
Feb 13, 2026Option exercise+14,687––112,546
Jessie Hanrahan
Chief Regulatory Officer
Feb 13, 2026Option exercise+8,125––78,452
Gabriel Brooks
Chief Medical Officer
Feb 13, 2026Option exercise+10,937––95,029
Kevin Tan
CFO & Treasurer
Feb 13, 2026Option exercise+10,625––104,826
Ilan Ganot
Director
Feb 4, 2026Sale(10b5-1 plan)−7,205$6.44$46.40K25,271
Gabriel Brooks
Chief Medical Officer
Feb 4, 2026Sale(10b5-1 plan)−12,616$6.44$81.25K84,092
Alexander Cumbo
President and CEO, Director
Feb 4, 2026Sale(10b5-1 plan)−48,913$6.44$315.00K222,018
Kevin Tan
CFO & Treasurer
Feb 4, 2026Sale(10b5-1 plan)−14,783$6.44$95.20K94,201
Paul Herzich
Chief Technology Officer
Feb 4, 2026Sale(10b5-1 plan)−10,905$6.44$70.23K69,067
David T. Howton
Chief Operating Officer
Feb 4, 2026Sale(10b5-1 plan)−18,894$6.44$121.68K97,859
Jessie Hanrahan
Chief Regulatory Officer
Feb 4, 2026Sale(10b5-1 plan)−12,348$6.44$79.52K70,327
David T. Howton
Chief Operating Officer
Feb 2, 2026Sale(10b5-1 plan)−37,771$6.44$243.25K116,753
Kevin Tan
CFO & Treasurer
Feb 2, 2026Sale(10b5-1 plan)−26,837$6.44$172.83K108,984
Jessie Hanrahan
Chief Regulatory Officer
Feb 2, 2026Sale(10b5-1 plan)−26,535$6.44$170.89K82,675
Gabriel Brooks
Chief Medical Officer
Feb 2, 2026Sale(10b5-1 plan)−28,335$6.44$182.48K96,708
Alexander Cumbo
President and CEO, Director
Feb 2, 2026Sale(10b5-1 plan)−80,258$6.44$516.86K270,931
Paul Herzich
Chief Technology Officer
Feb 2, 2026Sale(10b5-1 plan)−26,250$6.44$169.05K79,972
Ilan Ganot
Director
Jan 31, 2026Option exercise+15,000––32,476
David T. Howton
Chief Operating Officer
Jan 31, 2026Option exercise+42,275––154,254
Kevin Tan
CFO & Treasurer
Jan 31, 2026Option exercise+33,075––135,821
Jessie Hanrahan
Chief Regulatory Officer
Jan 31, 2026Option exercise+27,625––109,210
Gabriel Brooks
Chief Medical Officer
Jan 31, 2026Option exercise+28,225––125,043
Alexander Cumbo
President and CEO, Director
Jan 31, 2026Option exercise+100,400––351,189
Paul Herzich
Chief Technology Officer
Jan 31, 2026Option exercise+24,675––106,222
David T. Howton
Chief Operating Officer
Jan 29, 2026Option exercise+79,341––112,249
Kevin Tan
CFO & Treasurer
Jan 29, 2026Option exercise+56,646––102,746
Jessie Hanrahan
Chief Regulatory Officer
Jan 29, 2026Option exercise+54,925––81,585
Gabriel Brooks
Chief Medical Officer
Jan 29, 2026Option exercise+58,847––96,818
Alexander Cumbo
President and CEO, Director
Jan 29, 2026Option exercise+169,401––250,789
Paul Herzich
Chief Technology Officer
Jan 29, 2026Option exercise+54,925––81,547
Ilan Ganot
Director
Jan 28, 2026Sale(10b5-1 plan)−191$6.59$1.26K17,476
Ilan Ganot
Director
Jan 27, 2026Option exercise+389––17,667
Ilan Ganot
Director
Jan 27, 2026Option exercise+3,884––99,297
Kevin Tan
CFO & Treasurer
Jan 13, 2026Sale(10b5-1 plan)−5,704$5.27$30.06K46,100
Kevin Tan
CFO & Treasurer
Jan 9, 2026Option exercise+11,250––51,804
Ian F. Smith
Director
Jan 6, 2026Option exercise+4,573––131,264
Ilan Ganot
Director
Jan 5, 2026Sale−1,053$5.43$5.72K17,278
Ilan Ganot
Director
Jan 3, 2026Option exercise+2,994––18,331
David T. Howton
Chief Operating Officer
Dec 3, 2025Sale(10b5-1 plan)−4,932$5.11$25.20K32,908
Paul Herzich
Chief Technology Officer
Dec 3, 2025Sale(10b5-1 plan)−2,701$5.11$13.80K26,622
Alexander Cumbo
President and CEO, Director
Dec 3, 2025Sale(10b5-1 plan)−10,808$5.11$55.23K81,388
Jessie Hanrahan
Chief Regulatory Officer
Dec 3, 2025Sale(10b5-1 plan)−4,483$5.11$22.91K26,660
David T. Howton
Chief Operating Officer
Dec 2, 2025Option exercise+13,051––37,840
Paul Herzich
Chief Technology Officer
Dec 2, 2025Option exercise+7,239––29,323
Alexander Cumbo
President and CEO, Director
Dec 2, 2025Option exercise+28,612––92,196

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.93%
13M shares short
Days to cover
10.7
At 1M shares a day
Change since last report
+8.2%
From 12M shares
Short volume, 20 days
72.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Solid Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,166 shares on Sep 2, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jessie Hanrahan
Officer
Feb 18, 20264,134$24.07KFeb 18, 2026Settlement of vested restricted stock units
Alexander Cumbo
Officer, Director
Feb 18, 202616,644$96.92KFeb 18, 2026Settlement of vested restricted stock units
David T. Howton
Officer
Feb 18, 20267,469$43.49KFeb 18, 2026Settlement of vested restricted stock units
Gabriel Brooks
Officer
Feb 18, 20265,563$32.40KFeb 18, 2026Settlement of vested restricted stock units
Kevin Tan
Officer
Feb 18, 20265,404$31.47KFeb 18, 2026Settlement of vested restricted stock units
Ilan Ganot
Director
Feb 18, 20262,658$15.75KFeb 18, 2026Settlement of vested restricted stock units indirectly held by the reporting person through his wife, Ms. Ganot
Paul Herzich
Officer
Feb 18, 20263,616$21.06KFeb 18, 2026Settlement of vested restricted stock units
Gabriel Brooks
Officer
Feb 4, 202612,616$81.27KFeb 4, 2026Settlement of vested restricted stock units
Jessie Hanrahan
Officer
Feb 4, 202612,348$79.54KFeb 4, 2026Settlement of vested restricted stock units
David T. Howton
Officer
Feb 4, 202618,894$121.71KFeb 4, 2026Settlement of vested restricted stock units
Alexander Cumbo
Officer, Director
Feb 4, 202648,913$315.08KFeb 4, 2026Settlement of vested restricted stock units
Ilan Ganot
Director
Feb 4, 20267,205$46.41KFeb 4, 2026Settlement of vested restricted stock units indirectly held by the reporting person by his wife, Ms. Ganot
Paul Herzich
Officer
Feb 4, 202610,905$70.25KFeb 4, 2026Settlement of vested restricted stock units
Kevin Tan
Officer
Feb 4, 202614,783$95.23KFeb 4, 2026Settlement of vested restricted stock units
Jessie Hanrahan
Officer
Feb 2, 202626,535$170.80KFeb 2, 2026Settlement of performance shares

See a number that looks wrong?